AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), it has emerged.
Specifically, the drug has been recommended for the treatment of moderate to severe plaque psoriasis in adults who are eligible for systemic therapy.
